Arcturus Therapeutics Holdings (ARCT) Revenue (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has reported Revenue for 9 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 89.54% year-over-year to $3.0 million; the trailing twelve-month figure through Jun 2026 stood at $29.4 million (down 75.95% YoY), and the FY2025 full-year result was $82.0 million, down 46.14% from the prior year.
• Revenue advanced to $3.0 million in Q2 2026 per ARCT's latest filing, from $2.1 million in the prior quarter.
• Across five years, Revenue topped out at $160.3 million in Q4 2022 and bottomed at $2.1 million in Q1 2026.
• Historically, Revenue has averaged $34.0 million across 5 years, with a median of $27.7 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Revenue jumped 2666.53% in 2022, then slumped 92.99% in 2026.
• Over 5 years, Revenue stood at $160.3 million in 2022, then slumped by 80.75% to $30.9 million in 2023, then fell by 26.22% to $22.8 million in 2024, then tumbled by 68.39% to $7.2 million in 2025, then plunged by 58.88% to $3.0 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $3.0 million, $2.1 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.